Investigational drug · Phase 2
Vortosiran
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Vortosiran"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vortosiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Thromboembolism (VTE)
- Cancer
- Pulmonary Embolism (Diagnosis)
- Non-valvular Atrial Fibrillation (AF)
Approved drugs for the same conditions: Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Oncology · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Vortosiran" as an intervention, largest first.
- Vortosiran in Atrial FibrillationPivotal-lookingNot yet recruiting
Ribocure Pharmaceuticals ABIndustry
NCT07870889 · 150 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2028
Drug: Vortosiran; Vortosiran and 1 more · For: Non-valvular Atrial Fibrillation (AF)
Sites: Frederiksberg, Denmark; Herlev, Denmark; Grålum, Norway · 15 sites in all
- Vortosiran for VTE PreventionPivotal-lookingNot yet recruiting
Ribocure Pharmaceuticals ABIndustry
NCT07850453 · 150 participants (planned) · Start Oct 2026 · Primary completion Jul 2027
Drug: Vortosiran; Placebo · For: Venous Thromboembolism (VTE); Cancer; Pulmonary Embolism (Diagnosis)
Sites: Pazardzhik, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 30 sites in all
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNot yet recruiting
Suzhou Ribo Life Science Co. Ltd.Industry
NCT07930767 · 30 participants (planned) · Start Dec 2026 · Primary completion Aug 2027
Drug: RBD4059; Placebo · For: Healthy
Newest research
PubMed records naming it or its code names, newest first.
- RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran).
Gabrielsen A, Ueckert S, Nilsson C, et al. · Blood Adv 2026
Also in development for Venous Thromboembolism (VTE)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.